5.86
-0.01 (-0.26%)
| 前收盘价格 | 5.88 |
| 收盘价格 | 5.88 |
| 成交量 | 2,287,917 |
| 平均成交量 (3个月) | 3,062,567 |
| 市值 | 1,683,935,616 |
| 价格/销量 (P/S) | 302.09 |
| 股市价格/股市净资产 (P/B) | 8.89 |
| 52周波幅 | |
| 利润日期 | 12 Aug 2026 |
| 营业利益率 (TTM) | -930.54% |
| 稀释每股收益 (EPS TTM) | -0.340 |
| 季度收入增长率 (YOY) | -32.50% |
| 总债务/股东权益 (D/E MRQ) | 111.93% |
| 流动比率 (MRQ) | 5.35 |
| 营业现金流 (OCF TTM) | -83.45 M |
| 杠杆自由现金流 (LFCF TTM) | -52.28 M |
| 资产报酬率 (ROA TTM) | -35.91% |
| 股东权益报酬率 (ROE TTM) | -159.34% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Taysha Gene Therapies, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.00 |
|
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 12.11% |
| 机构持股比例 | 67.23% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合